The addition of induction chemotherapy with etoposide, ifosfamide, and cisplatin failed to improve therapeutic outcome of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer - Single institution retrospective analysis

Neoplasma

Volumn 53, Issue 1, 2006, Pages 30-36

  Lee, H W ^a   Choi, J H ^a   Lim, H Y ^a   Park, J S ^a   Kim, H C ^a   Kang, S ^a   Oh, Y T ^a   Chun, M ^a   Sheen, S S ^a   Oh, Y J ^a   Park, K J ^a   Hwang, S C ^a  

^a Ajou University School of Medicine   (South Korea)

Author keywords

Concurrent chemoradiotherapy; Induction chemotherapy; Locally advanced; Non small cell lung cancer

Indexed keywords

CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE;

ADD ON THERAPY; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; COMPARATIVE STUDY; CONSTIPATION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG FATALITY; ESOPHAGITIS; FEMALE; HUMAN; INFECTIOUS PNEUMONIA; INOPERABLE CANCER; LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PROGNOSIS; PYREXIA IDIOPATHICA; RADIATION DERMATITIS; RADIATION DOSE; RADIATION PNEUMONIA; RADIOCHEMOTHERAPY; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TRACHEOESOPHAGEAL FISTULA; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

EID: 32144452563     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. BAE J-M, WON Y-J, JUNG K-W, SUH K-A, YUN Y-H et al. Survival of Korean cancer patients diagnosed in 1995. Cancer Res Treat 2002; 34: 319-325.
2. JOHNSON DH, TURRISI AT. Combined modality treatment for locally advanced, unresectable non-small cell lung cancer. In: Pass HI, Mitchell JB, Johnson DH, Turrisi AT, Minna JD, editors. Lung Cancer: principles and practice. 2nd ed. Philadelphia: Lippincott Williams and Wilkins 2000: 910-920.
3. LE CHEVALIER T, ARRIAGADA R, QUOIX E, RUFFIE P, MARTIN M et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991; 83: 417-423.
4. SCHAAKE-KONING C, VAN DEN BOGAERT W, DALESIO O, FESTEN J, HOOGENHOUT J et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992; 326: 524-530.
5. DILLMAN RO, HERNDON J, SEAGREN SL, EATON WL Jr, GREEN MR. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst 1996; 88: 1210-1215.
6. PRITCHARD RS, ANTHONY SP. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer, a meta-analysis. Ann Intern Med 1996; 125: 723-729.
7. SAUSE W, KOLESAR P, TAYLOR S IV, JOHNSON D, LIVINGSTON R et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000; 117: 358-364.
8. KOMAKI R, SCOTT CB, SAUSE WT, JOHNSON DH, TAYLOR SG IV et al. Induction cisplatin/vinblastine and irradiation vs. irradiation in unresectable squamous cell lung cancer: failure patterns by cell type in RTOG 88-08/ECOG 4588. Int J Radiat Oncol Biol Phys 1997; 39: 537-544.
9. ARDIZZONI A, GROSSI F, SCOLARO T, GIUDICI S, FOPPIANO F et al. Induction chemotherapy followed by concurrent standard radiotherapy and daily low-dose cisplatin in locally advanced non-small-cell lung cancer. Br J Cancer 1999; 81: 310-315.
10. AMERICAN JOINT COMMITTEE ON CANCER. AJCC cancer staging manual. 6th ed. New York: Springer 2002.
11. MILLER AB, HOOGSTRATEN B, STAQUET M, WINKLER A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
12. NATIONAL CANCER INSTITUTE. Common toxicity criteria (version 2), Division of Cancer Treatment and Diagnosis, National Cancer Institute, USA: Bethesda, 1999.
13. KAPLAN EL, MEIER P. Non-parametric estimation from incomplete observations. J Am Statist Assoc 1958; 53: 457-481.
14. COX DR. Regression models and life tables. J R Statist Soc 1972; 34: 187-220.
15. FURUSE K, FUKUOKA M, KAWAHARA M, NISHIKAWA H, TAKADA Y et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999; 17: 2692-2699.
16. ZATLOUKAL PV, PETRUZELKA L, ZEMANOVA M, HAVEL L, JANKU F et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 2004; 46: 87-98.
17. CURRAN WJ, SCOTT CB, LANGER CJ, KOMAKI R, LEE JS et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III nsclc: RTOG 9410. Proc Am Soc Clin Oncol 2004; 22: 621.
18. KOMAKI R, SCOTT C, ETTINGER D, LEE JS, FOSSELLA FV et al. Randomized study of chemotherapy/radiation therapy combinations for favorable patients with locally advanced inoperable nonsmall cell lung cancer: Radiation Therapy Oncology Group (RTOG) 92-04. Int J Radiat Oncol Biol Phys 1997; 38: 149-155.
19. KOMAKI R, SEIFERHELD W, ETTINGER D, LEE JS, MOVSAS B et al. Randomized phase II chemotherapy and radiotherapy trial for patients with locally advanced inoperable non-small-cell lung cancer: long-term follow-up of RTOG 92-04. Int J Radiat Oncol Biol Phys 2002; 53: 548-557.
20. VOKES EE, HERNDON JE, KELLEY MJ, WATSON D, CICCHETTI MG et al. Induction chemotherapy followed by concomitant chemoradiotherapy (CT/XRT) versus CT/XRT alone for regionally advanced unresectable non-small cell lung cancer (NSCLC): initial analysis of a randomized phase III trial. Proc Am Soc Clin Oncol 2004; 22: 618.
21. SAUSE WT, SCOTT C, TAYLOR S, BYHARDT RW, BANKER FL et al. Phase II trial of combination chemotherapy and irradiation in non-small-cell lung cancer, Radiation Therapy Oncology Group 88-04. Am J Clin Oncol 1992; 15: 163-167.
22. SCHILLER JA. Chemotherapy for advanced non-small cell lung cancer. In: Pass HI, Mitchell JB, Johnson DH, Turrisi AT, Minna JD, editors. Lung Cancer: principles and practice. 2nd ed. Philadelphia: Lippincott Williams and Wilkins 2000: 889-902.
23. CHOY H, CURRAN WJ, SCOTT CB, BONOMI P, TRAVIS P et al. Preliminary report of locally advanced multimodality protocol (LAMP): ACR427: a randomized phase II study of three chemo-radiation regimens with paclitaxel, carboplatin, and thoracic radiation (TRT) for patients with locally advanced non small cell lung cancer (LA-NSCLC). Proc Am Soc Clin Oncol 2002; 21: 291.
24. SCHILD SE, STELLA PJ, GEYER SM, BONNER JA, MARKS RS et al. Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2002; 54: 370-378.
25. CLAMON G, HERNDON J, COOPER R, CHANG AY, ROSENMAN J et al. Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol 1999; 17: 4-11.